UC - Ulcerative Colitis
9
2
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
Enabling Microbiomics- Driven Personalized Nutrition
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants
Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis
Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
Impact of Therapeutic Intervention on Quality of Life in Patients With Ulcerative Colitis
Low FODMAP Diet on Nutritional Status, Disease Activity and Gut Microbiota in IBS and UC With Normal or Overweight BMI